Perrigo Company PLC reported fourth-quarter 2025 revenue of $1.32 billion, driven by growth in its specialty pharmaceuticals segment and continued cost optimization across its global operations. The results mark a 5.2% year-over-year increase, with adjusted EBITDA reaching $318 million.
- Q4 2025 revenue totaled $1.32 billion, up 5.2% year-over-year
- Adjusted EBITDA increased to $318 million, a 7.4% rise from Q4 2024
- Specialty pharmaceuticals segment grew 9.1% YoY, contributing 41% of total revenue
- Ongoing cost reduction measures led to a 12% improvement in operating expenses
- Cash flow from operations reached $245 million for the quarter
- Full-year 2025 revenue was $5.08 billion, above the midpoint of guidance
Perrigo Company PLC delivered consolidated revenue of $1.32 billion for the fourth quarter of 2025, surpassing analyst expectations and reflecting progress in its restructuring initiatives. The company attributed the growth to strong performance in its specialty generics and over-the-counter (OTC) divisions, particularly in the U.S. and European markets. Adjusted EBITDA for the period reached $318 million, representing a 7.4% increase compared to the same quarter in 2024.